Secondary bladder cancer after anticancer therapy for prostate cancer

Reduced comorbidity after androgen-deprivation therapy

masaki shiota, Akira Yokomizo, ario takeuchi, Kenjiro Imada, Keijiro Kiyoshima, Junichi Inokuchi, Katsunori Tatsugami, Ohga Saiji, Katsumasa Nakamura, Hiroshi Honda, Seiji Naito

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Radiotherapy for prostate cancer is associated with an increased incidence of secondary bladder cancer (BC). We investigated the incidence, clinicopathological characteristics, and prognosis of BC after radiotherapy, surgical therapy, and primary androgen-deprivation therapy (ADT) for prostate cancer. This study included 1,334 Japanese patients with prostate cancer treated with radiotherapy (n=631), surgical therapy (n=437), and primary ADT (n=266). During the median follow-up period of 51.2, 44.8, and 45.5 months, secondary BC occurred in 14 (2.2%), 5 (1.1%), and 0 (0%) of patients with prostate cancer treated with radiotherapy, surgical therapy, and primary ADT, respectively. The 10-year BC-free survival rate was 91.3% in the radiotherapy group, 97.4% in the surgical therapy group, and 100% in the primary ADT group. The rates of intravesical recurrence, progression to muscle-invasive BC, and BC-specific death might be higher in secondary BC after radiotherapy compared with after surgical therapy. There was a significant difference in the incidence of secondary BC among different therapeutic modalities for prostate cancer in Japanese men, indicating significantly lower comorbidity rates of secondary BC after primary ADT for prostate cancer compared with radiotherapy.

Original languageEnglish
Pages (from-to)14710-14719
Number of pages10
JournalOncotarget
Volume6
Issue number16
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Urinary Bladder Neoplasms
Androgens
Comorbidity
Prostatic Neoplasms
Radiotherapy
Therapeutics
Group Psychotherapy
Incidence
Survival Rate
Recurrence
Muscles

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Secondary bladder cancer after anticancer therapy for prostate cancer : Reduced comorbidity after androgen-deprivation therapy. / shiota, masaki; Yokomizo, Akira; takeuchi, ario; Imada, Kenjiro; Kiyoshima, Keijiro; Inokuchi, Junichi; Tatsugami, Katsunori; Saiji, Ohga; Nakamura, Katsumasa; Honda, Hiroshi; Naito, Seiji.

In: Oncotarget, Vol. 6, No. 16, 01.01.2015, p. 14710-14719.

Research output: Contribution to journalArticle

shiota, masaki ; Yokomizo, Akira ; takeuchi, ario ; Imada, Kenjiro ; Kiyoshima, Keijiro ; Inokuchi, Junichi ; Tatsugami, Katsunori ; Saiji, Ohga ; Nakamura, Katsumasa ; Honda, Hiroshi ; Naito, Seiji. / Secondary bladder cancer after anticancer therapy for prostate cancer : Reduced comorbidity after androgen-deprivation therapy. In: Oncotarget. 2015 ; Vol. 6, No. 16. pp. 14710-14719.
@article{377faf62e29048d185454f26144f38ee,
title = "Secondary bladder cancer after anticancer therapy for prostate cancer: Reduced comorbidity after androgen-deprivation therapy",
abstract = "Radiotherapy for prostate cancer is associated with an increased incidence of secondary bladder cancer (BC). We investigated the incidence, clinicopathological characteristics, and prognosis of BC after radiotherapy, surgical therapy, and primary androgen-deprivation therapy (ADT) for prostate cancer. This study included 1,334 Japanese patients with prostate cancer treated with radiotherapy (n=631), surgical therapy (n=437), and primary ADT (n=266). During the median follow-up period of 51.2, 44.8, and 45.5 months, secondary BC occurred in 14 (2.2{\%}), 5 (1.1{\%}), and 0 (0{\%}) of patients with prostate cancer treated with radiotherapy, surgical therapy, and primary ADT, respectively. The 10-year BC-free survival rate was 91.3{\%} in the radiotherapy group, 97.4{\%} in the surgical therapy group, and 100{\%} in the primary ADT group. The rates of intravesical recurrence, progression to muscle-invasive BC, and BC-specific death might be higher in secondary BC after radiotherapy compared with after surgical therapy. There was a significant difference in the incidence of secondary BC among different therapeutic modalities for prostate cancer in Japanese men, indicating significantly lower comorbidity rates of secondary BC after primary ADT for prostate cancer compared with radiotherapy.",
author = "masaki shiota and Akira Yokomizo and ario takeuchi and Kenjiro Imada and Keijiro Kiyoshima and Junichi Inokuchi and Katsunori Tatsugami and Ohga Saiji and Katsumasa Nakamura and Hiroshi Honda and Seiji Naito",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.3817",
language = "English",
volume = "6",
pages = "14710--14719",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "16",

}

TY - JOUR

T1 - Secondary bladder cancer after anticancer therapy for prostate cancer

T2 - Reduced comorbidity after androgen-deprivation therapy

AU - shiota, masaki

AU - Yokomizo, Akira

AU - takeuchi, ario

AU - Imada, Kenjiro

AU - Kiyoshima, Keijiro

AU - Inokuchi, Junichi

AU - Tatsugami, Katsunori

AU - Saiji, Ohga

AU - Nakamura, Katsumasa

AU - Honda, Hiroshi

AU - Naito, Seiji

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Radiotherapy for prostate cancer is associated with an increased incidence of secondary bladder cancer (BC). We investigated the incidence, clinicopathological characteristics, and prognosis of BC after radiotherapy, surgical therapy, and primary androgen-deprivation therapy (ADT) for prostate cancer. This study included 1,334 Japanese patients with prostate cancer treated with radiotherapy (n=631), surgical therapy (n=437), and primary ADT (n=266). During the median follow-up period of 51.2, 44.8, and 45.5 months, secondary BC occurred in 14 (2.2%), 5 (1.1%), and 0 (0%) of patients with prostate cancer treated with radiotherapy, surgical therapy, and primary ADT, respectively. The 10-year BC-free survival rate was 91.3% in the radiotherapy group, 97.4% in the surgical therapy group, and 100% in the primary ADT group. The rates of intravesical recurrence, progression to muscle-invasive BC, and BC-specific death might be higher in secondary BC after radiotherapy compared with after surgical therapy. There was a significant difference in the incidence of secondary BC among different therapeutic modalities for prostate cancer in Japanese men, indicating significantly lower comorbidity rates of secondary BC after primary ADT for prostate cancer compared with radiotherapy.

AB - Radiotherapy for prostate cancer is associated with an increased incidence of secondary bladder cancer (BC). We investigated the incidence, clinicopathological characteristics, and prognosis of BC after radiotherapy, surgical therapy, and primary androgen-deprivation therapy (ADT) for prostate cancer. This study included 1,334 Japanese patients with prostate cancer treated with radiotherapy (n=631), surgical therapy (n=437), and primary ADT (n=266). During the median follow-up period of 51.2, 44.8, and 45.5 months, secondary BC occurred in 14 (2.2%), 5 (1.1%), and 0 (0%) of patients with prostate cancer treated with radiotherapy, surgical therapy, and primary ADT, respectively. The 10-year BC-free survival rate was 91.3% in the radiotherapy group, 97.4% in the surgical therapy group, and 100% in the primary ADT group. The rates of intravesical recurrence, progression to muscle-invasive BC, and BC-specific death might be higher in secondary BC after radiotherapy compared with after surgical therapy. There was a significant difference in the incidence of secondary BC among different therapeutic modalities for prostate cancer in Japanese men, indicating significantly lower comorbidity rates of secondary BC after primary ADT for prostate cancer compared with radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84931080184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931080184&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.3817

DO - 10.18632/oncotarget.3817

M3 - Article

VL - 6

SP - 14710

EP - 14719

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 16

ER -